Advertisement

Clinical Rheumatology

, Volume 34, Issue 1, pp 71–79 | Cite as

Identification of interferon-inducible genes as diagnostic biomarker for systemic lupus erythematosus

  • Xuebing FengEmail author
  • Jing Huang
  • Yan Liu
  • Lihui Xiao
  • Dandan Wang
  • Bingzhu Hua
  • Betty P. Tsao
  • Lingyun SunEmail author
Original Article

Abstract

The identification of biomarkers helps to perform early diagnosis, thus benefits the outcome of patients with systemic lupus erythematosus (SLE), in which delayed treatment has been proposed as an independent adverse prognostic factor. In this study, we assessed the values of expression levels of five type I interferon (IFN)-inducible genes (LY6E, OAS1, OASL, MX1, and ISG15) and total IFN score for the diagnosis of SLE. Quantitative real-time PCR was applied to determine gene expressions at transcription level in peripheral blood from 69 SLE patients, 42 patients with other connective tissue diseases, and 26 normal controls. Expressions of five genes and IFN score, calculated according to the expressions of IFN-inducible genes, were all significantly increased in SLE patients compared to those in normal subjects and disease controls. IFN score was not related to age, gender, and the dose of steroids, but weakly correlated with SLE disease activity index. None of the gene expression was associated with concomitant infection status or elevated antibodies against Epstein–Barr (EB) virus in SLE. Both modified IFN score (calculated by the expression of three major IFN-inducible genes) and LY6E level showed good diagnostic accuracy in discriminating between SLE patients and disease controls as well as normal subjects (area under the receiver operating characteristic curve was 0.812 and 0.815, respectively), with 70–80 % specificity and 70–80 % sensitivity at the cutoff of 2.37 and 3.23. In conclusion, high IFN-inducible gene expression is constitutional for SLE patients. The modified IFN score or the LY6E level alone may serve as good biomarkers for SLE diagnosis.

Keywords

Diagnosis Interferon-inducible genes Systemic lupus erythematosus 

Notes

Acknowledgments

We thank all the patients with SLE or other connective tissue disease and healthy volunteers who participated in this study. This work was supported by the National Natural Science Foundation of China (grant number 81172846, 81373198) and Jiangsu Province’s Key Provincial Talents Program. BPT was supported by RO1 43814 from the NIAMS NIH. Editing assistance was provided by Erika Magdangal, UCLA.

Disclosures

None.

References

  1. 1.
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25(11):1271–1277PubMedCrossRefGoogle Scholar
  2. 2.
    Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725PubMedCrossRefGoogle Scholar
  3. 3.
    Agmon-Levin N, Mosca M, Petri M, Shoenfeld Y (2012) Systemic lupus erythematosus one disease or many? Autoimmun Rev 11(8):593–595PubMedCrossRefGoogle Scholar
  4. 4.
    Olsen NJ, Li QZ, Quan J, Wang L, Mutwally A, Karp DR (2012) Autoantibody profiling to follow evolution of lupus syndromes. Arthritis Res Ther 14(4):R174PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Feng X, Zou Y, Pan W, Wang X, Wu M, Zhang M et al (2014) Associations of clinical features and prognosis with age at disease onset in patients with systemic lupus erythematosus. Lupus 23(3):327–334PubMedCrossRefGoogle Scholar
  6. 6.
    Feng X, Zou Y, Pan W, Wang X, Wu M, Zhang M et al (2011) Prognostic indicators of hospitalized patients with systemic lupus erythematosus: a large retrospective multicenter study in China. J Rheumatol 38(7):1289–1295PubMedCrossRefGoogle Scholar
  7. 7.
    Schiffenbauer J, Hahn B, Weisman MH, Simon LS (2004) Biomarkers, surrogate markers, and design of clinical trials of new therapies for systemic lupus erythematosus. Arthritis Rheum 50(8):2415–2422PubMedCrossRefGoogle Scholar
  8. 8.
    Ahearn JM, Liu CC, Kao AH, Manzi S (2012) Biomarkers for systemic lupus erythematosus. Transl Res 159(4):326–342PubMedCrossRefGoogle Scholar
  9. 9.
    Nikpour M, Dempsey AA, Urowitz MB, Gladman DD, Barnes DA (2008) Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus. Ann Rheum Dis 67(8):1069–1075PubMedCrossRefGoogle Scholar
  10. 10.
    Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ et al (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 100(5):2610–2615PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Bronson PG, Chaivorapol C, Ortmann W, Behrens TW, Graham RR (2012) The genetics of type I interferon in systemic lupus erythematosus. Curr Opin Immunol 24(5):530–537PubMedCrossRefGoogle Scholar
  12. 12.
    Liu Z, Bethunaickan R, Huang W, Lodhi U, Solano I, Madaio MP et al (2011) Interferon-alpha accelerates murine systemic lupus erythematosus in a T cell-dependent manner. Arthritis Rheum 63(1):219–229PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Crow MK (2010) Type I, interferon in organ-targeted autoimmune and inflammatory diseases. Arthritis Res Ther 12(Suppl 1):S5PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Bauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, Ortmann WA et al (2006) Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 3(12):e491PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS et al (2006) Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 54(9):2951–2962PubMedCrossRefGoogle Scholar
  16. 16.
    Elkon KB, Wiedeman A (2012) Type I IFN system in the development and manifestations of SLE. Curr Opin Rheumatol 24(5):499–505PubMedCrossRefGoogle Scholar
  17. 17.
    Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK (2005) Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 52(5):1491–1503PubMedCrossRefGoogle Scholar
  18. 18.
    Landolt-Marticorena C, Bonventi G, Lubovich A, Ferguson C, Unnithan T, Su J et al (2009) Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis 68(9):1440–1446PubMedCrossRefGoogle Scholar
  19. 19.
    Petri M, Singh S, Tesfasyone H, Dedrick R, Fry K, Lal P et al (2009) Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus 18(11):980–989PubMedCrossRefGoogle Scholar
  20. 20.
    Petri M, Wallace DJ, Spindler A, Chindalore V, Kalunian K, Mysler E et al (2013) Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum 65(4):1011–1021PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35(6):630–640PubMedCrossRefGoogle Scholar
  22. 22.
    Xia J, Broadhurst DI, Wilson M, Wishart DS (2013) Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics 9(2):280–299PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Draborg AH, Duus K, Houen G (2012) Epstein-Barr virus and systemic lupus erythematosus. Clin Dev Immunol 2012:370516PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK (2007) High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 8(6):492–502PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Niewold TB (2011) Interferon alpha as a primary pathogenic factor in human lupus. J Interferon Cytokine Res 31(12):887–892PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Fu Q, Zhao J, Qian X, Wong JL, Kaufman KM, Yu CY et al (2011) Association of a functional IRF7 variant with systemic lupus erythematosus. Arthritis Rheum 63(3):749–754PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Jacob CO, Zhu J, Armstrong DL, Yan M, Han J, Zhou XJ et al (2009) Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci U S A 106(15):6256–6261PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Lee-Kirsch MA, Gong M, Chowdhury D, Senenko L, Engel K, Lee YA et al (2007) Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet 39(9):1065–1067PubMedCrossRefGoogle Scholar
  29. 29.
    Ramos PS, Williams AH, Ziegler JT, Comeau ME, Guy RT, Lessard CJ et al (2011) Genetic analyses of interferon pathway-related genes reveal multiple new loci associated with systemic lupus erythematosus. Arthritis Rheum 63(7):2049–2057PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW et al (2007) STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 357(10):977–986PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Kariuki SN, Crow MK, Niewold TB (2008) The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus. Arthritis Rheum 58(9):2818–2823PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Sigurdsson S, Nordmark G, Goring HH, Lindroos K, Wiman AC, Sturfelt G et al (2005) Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 76(3):528–537PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Graham RR, Kyogoku C, Sigurdsson S, Vlasova IA, Davies LR, Baechler EC et al (2007) Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci U S A 104(16):6758–6763PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Nacionales DC, Kelly-Scumpia KM, Lee PY, Weinstein JS, Lyons R, Sobel E et al (2007) Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum 56(11):3770–3783PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Ronnblom L (2010) Potential role of IFNalpha in adult lupus. Arthritis Res Ther 12(Suppl 1):S3PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Crow MK, Wohlgemuth J (2003) Microarray analysis of gene expression in lupus. Arthritis Res Ther 5(6):279–287PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C et al (2011) Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 70(11):2029–2036PubMedCrossRefGoogle Scholar
  38. 38.
    Vakaloglou KM, Mavragani CP (2011) Activation of the type I interferon pathway in primary Sjogren’s syndrome: an update. Curr Opin Rheumatol 23(5):459–464PubMedCrossRefGoogle Scholar
  39. 39.
    Papatriantafyllou M (2013) Infection: the interferon paradox. Nat Rev Immunol 13(6):392PubMedCrossRefGoogle Scholar
  40. 40.
    Harley JB, James JA (2010) Everyone comes from somewhere: systemic lupus erythematosus and Epstein-Barr virus induction of host interferon and humoral anti-Epstein-Barr nuclear antigen 1 immunity. Arthritis Rheum 62(6):1571–1575PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Kyogoku C, Grun J, Alexander T, Biesen R, Hiepe F, Haupl T et al (2012) Cell-type specific type I interferon signatures in systemic lupus erythematosus and viral infection: what makes the difference? Arthritis Rheum 64(Suppl 10):979Google Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2014

Authors and Affiliations

  • Xuebing Feng
    • 1
    Email author
  • Jing Huang
    • 1
  • Yan Liu
    • 1
  • Lihui Xiao
    • 1
  • Dandan Wang
    • 1
  • Bingzhu Hua
    • 1
  • Betty P. Tsao
    • 2
  • Lingyun Sun
    • 1
    Email author
  1. 1.Department of RheumatologyThe Affiliated Drum Tower Hospital of Nanjing University Medical SchoolNanjingChina
  2. 2.Division of RheumatologyDavid Geffen School of Medicine at UCLALos AngelesUSA

Personalised recommendations